地肤通乳散治疗奶牛乳房炎临床疗效及作用靶点预测

为探讨地肤通乳散治疗奶牛乳房炎的临床效果、抗菌活性及作用机制,先利用微量肉汤法测定地肤通乳散对奶牛乳房炎主要病原菌体外抗菌活性,再对患有乳房炎的奶牛进行治疗,观察治愈率和有效率,最后利用BATMAN、STRING、Cytoscape等数据库及软件对地肤通乳散治疗奶牛乳房炎作用靶点进行分析。结果显示,地肤通乳散对无乳链球菌抑制、杀灭浓度均为1.52 mg·mL^-1;对大肠埃希菌和金黄色葡萄球菌的最小抑制浓度为25 mg·mL^-1,最小杀菌浓度是最小抑制浓度的2倍;对奶牛乳房炎的治愈率为63.16%,有效率可达89.47%。地肤通乳散中共筛选得到21个活性化合物,对应靶点173个,枢纽靶点5个。上述结果说明,地肤通乳散对奶牛乳房炎主要病原菌体外抗菌活性较高,临床疗效确切,可能主要通过枢纽靶点5'-核苷酸酶、白介素-8、雌激素受体1、磷脂酰肌醇-4,5-二磷酸3-激酶催化亚基α和磷脂酰肌醇-4,5-二磷酸3-激酶催化亚基β作用于肿瘤坏死因子、Janus激酶2、Toll样受体4、原癌基因RelA、NF-κB亚基和趋化因子CXCL12来治疗奶牛乳房炎。

Clinical efficacy and mechanism prediction of Difutongrusan in treatment of bovine mastitis

To study the antibacterial activity, clinical effect and mechanism of Difutongrusan in the treatment of bovine mastitis. The antibacterial activities of Difutongrusan against the main pathogens of bovine mastitis were determined by the method of micro broth first, then the cows with mastitis were treated to observe the cure rate and the effective rate. Finally, BATMAN, STRING, Cytoscape databases and softwares were used to analyze the mechanism of treatment of bovine mastitis by Difutongrusan. The results showed that the MIC/MBC of Difutongrusan on Staphylococcus agalactiae was 1.52 mg·mL^-1, the MIC on Escherichia coli and Staphylococcus aureus was 25 mg·mL^-1, and the MBC was twice as high as the MIC; The clinical cure rate of bovine mastitis was 63.16% and the effective rate was 89.47%. A total of 21 active compounds were selected from Difutongrusan, with 173 corresponding targets and 5 pivotal targets. The results indicated that Difutongrusan could have high antibacterial activity in vitro against the main pathogenic bacteria of bovine mastitis, and the clinical efficacy could be definite, which may be mainly through the pivotal target NT5E, IL8, ESR1, PIK3CA and PIK3CB to treat bovine mastitis.